search
Back to results

A Single-Arm Trial of Neurovascular Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerotic Stenosis

Primary Purpose

Intracranial Atherosclerosis

Status
Active
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Neurovascular Drug-Eluting Balloon Dilatation Catheter
Sponsored by
Zhejiang Zylox Medical Device Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intracranial Atherosclerosis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 to 80 years, any gender;
  • Subject has symptomatic intracranial atherosclerotic stenosis that the degree of the artery stenosis is between 70% and 99% diagnosed by intracranial angiography;
  • The target stenotic artery locates in Internal Carotid Artery (intracranial segment), Middle Cerebral Artery (M1, M2), Basilar Artery, Vertebral Artery (intracranial segment);
  • Intracranial artery stenosis requiring interventional treatment is a single lesion;
  • Subject has at least two atherosclerosis risk factors including history or present hypertension, diabetes, hyperlipidemia, smoking, age>45;
  • modified Rankin Scale(mRS) score≤2 before enrollment;
  • Subject or guardian is able to understand the purpose of study, agree to provide follow-up data and has provided written informed consent.

Exclusion Criteria:

  • History of acute ischemic stroke within 2 weeks;
  • History of intracranial hemorrhage (including intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months;
  • Hypertension uncontrolled by medicine (Systolic pressure≥180 mmHg or diastolic pressure≥110 mmHg continuously);
  • Combined with the intracranial tumor, aneurysm or intracranial arteriovenous malformation;
  • The length of intracranial artery stenosis >10mm and extremely angulated >90°, which indicated by angiography;
  • History of stent intervention within the target lesion;
  • Allergic to heparin, sirolimus (i.e. rapamycin), contrast agents, aspirin, clopidogrel, anesthetics;
  • History of gastrointestinal hemorrhage within 6 months before signing the informed consent form, which is unable to receive antiplatelet therapy;
  • Platelet (PLT)<90*10^9/L;
  • Creatinine>250 umol/L;
  • International Normalized Ratio (INR)>1.5;
  • Female subject who is pregnant or breast-feeding, or who has a pregnancy plan within 12 months;
  • Expected life <12 months;
  • Unable to cooperate with or tolerate the interventional surgery;
  • Subject who has participated in other drug or device clinical trials or hasn't reached the primary end point;
  • Angiography indicates intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis;
  • Angiography indicates the vascular path is tortuous, the experimental device is difficult to reach the target position or be retracted;
  • Other circumstances judged by researchers that are not suitable for enrollment.

Sites / Locations

  • The First Affiliated Hospital of USTC
  • The First Affiliated Hospital of Wannan Medical College
  • Cangzhou Central hospital
  • Wuhan Hospital of Traditional Chinese and Western Medicine
  • General Hospital of Northen Theater Command
  • Linyi People's Hospital
  • The Affiliated Hospital of Qingdao University
  • West China Hospital, Sichuan University
  • Beijing Chao-Yang Hospital, Capital Medical University
  • Xuanwu Hospital Capital Medical University
  • Changhai Hospital of Shanghai

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Group A

Arm Description

Neurovascular Drug-Eluting Balloon Dilatation Catheter

Outcomes

Primary Outcome Measures

Restenosis rate of the target lesion
Subjects receive Digital Subtraction Angiography (DSA) / Computed Tomography Angiography (CTA) examination in 180 days to analyze whether the degree of stenosis is greater than or equal to 50%, if so, the target lesion restenosis happens.

Secondary Outcome Measures

Average stenosis degree of the target lesion
Subjects receive DSA / CTA examination in 180 days.
Success rate of device
After receiving DSA examination, success rate of device is defined as experimental device-neurovascular drug-eluting balloon dilatation catheter advanced on position successfully, balloon retracted smoothly after expanded, without balloon rupture and balloon catheter break, etc.
Success rate of surgery
After receiving DSA examination, success rate of surgery is defined as the final residual stenosis degree of target lesion<50% and modified thrombolysis in cerebral infarction score (mTICI) 2b/3, whether or not other additional treatments are applied.

Full Information

First Posted
June 24, 2021
Last Updated
October 13, 2022
Sponsor
Zhejiang Zylox Medical Device Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04949880
Brief Title
A Single-Arm Trial of Neurovascular Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerotic Stenosis
Official Title
The Efficacy and Safety Study for Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis Using Neurovascular Drug-Eluting Balloon Dilatation Catheter: A Prospective Multicentre Single-arm Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 2, 2021 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zhejiang Zylox Medical Device Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a trial designed to test the efficacy and safety of the Neurovascular Drug-Eluting Balloon Dilatation Catheter.
Detailed Description
This is a prospective multicentre single-arm trial conducted by 11 centers in mainland China. Approximately 132 subjects with symptomatic intracranial atherosclerotic stenosis receive endovascular treatment using the neurovascular drug-eluting balloon dilatation catheter designed by Zylox.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracranial Atherosclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
132 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Experimental
Arm Description
Neurovascular Drug-Eluting Balloon Dilatation Catheter
Intervention Type
Device
Intervention Name(s)
Neurovascular Drug-Eluting Balloon Dilatation Catheter
Intervention Description
The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
Primary Outcome Measure Information:
Title
Restenosis rate of the target lesion
Description
Subjects receive Digital Subtraction Angiography (DSA) / Computed Tomography Angiography (CTA) examination in 180 days to analyze whether the degree of stenosis is greater than or equal to 50%, if so, the target lesion restenosis happens.
Time Frame
180+60 days
Secondary Outcome Measure Information:
Title
Average stenosis degree of the target lesion
Description
Subjects receive DSA / CTA examination in 180 days.
Time Frame
180+60 days
Title
Success rate of device
Description
After receiving DSA examination, success rate of device is defined as experimental device-neurovascular drug-eluting balloon dilatation catheter advanced on position successfully, balloon retracted smoothly after expanded, without balloon rupture and balloon catheter break, etc.
Time Frame
Intraoperation
Title
Success rate of surgery
Description
After receiving DSA examination, success rate of surgery is defined as the final residual stenosis degree of target lesion<50% and modified thrombolysis in cerebral infarction score (mTICI) 2b/3, whether or not other additional treatments are applied.
Time Frame
Intraoperation
Other Pre-specified Outcome Measures:
Title
Incidence of device deficiency
Description
Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc.
Time Frame
within 180+60 days
Title
Incidence of stroke events
Description
Stroke events include hemorrhagic or ischemic stroke, transient cerebral ischemia.
Time Frame
7 days or at discharge / 30±7 days / 180+60 days
Title
Rate of death
Description
Subjects who died from any cause would be counted.
Time Frame
7 days or at discharge / 30±7 days / 180+60 days
Title
The rate of AE
Description
The definition of AE (Adverse Event) refers to ISO 14155.
Time Frame
within 180+60 days
Title
The rate of SAE
Description
The definition of SAE (Serious Adverse Event) refers to ISO 14155.
Time Frame
within 180+60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 to 80 years, any gender; Subject has symptomatic intracranial atherosclerotic stenosis that the degree of the artery stenosis is between 70% and 99% diagnosed by intracranial angiography; The target stenotic artery locates in Internal Carotid Artery (intracranial segment), Middle Cerebral Artery (M1, M2), Basilar Artery, Vertebral Artery (intracranial segment); Intracranial artery stenosis requiring interventional treatment is a single lesion; Subject has at least two atherosclerosis risk factors including history or present hypertension, diabetes, hyperlipidemia, smoking, age>45; modified Rankin Scale(mRS) score≤2 before enrollment; Subject or guardian is able to understand the purpose of study, agree to provide follow-up data and has provided written informed consent. Exclusion Criteria: History of acute ischemic stroke within 2 weeks; History of intracranial hemorrhage (including intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months; Hypertension uncontrolled by medicine (Systolic pressure≥180 mmHg or diastolic pressure≥110 mmHg continuously); Combined with the intracranial tumor, aneurysm or intracranial arteriovenous malformation; The length of intracranial artery stenosis >10mm and extremely angulated >90°, which indicated by angiography; History of stent intervention within the target lesion; Allergic to heparin, sirolimus (i.e. rapamycin), contrast agents, aspirin, clopidogrel, anesthetics; History of gastrointestinal hemorrhage within 6 months before signing the informed consent form, which is unable to receive antiplatelet therapy; Platelet (PLT)<90*10^9/L; Creatinine>250 umol/L; International Normalized Ratio (INR)>1.5; Female subject who is pregnant or breast-feeding, or who has a pregnancy plan within 12 months; Expected life <12 months; Unable to cooperate with or tolerate the interventional surgery; Subject who has participated in other drug or device clinical trials or hasn't reached the primary end point; Angiography indicates intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis; Angiography indicates the vascular path is tortuous, the experimental device is difficult to reach the target position or be retracted; Other circumstances judged by researchers that are not suitable for enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianmin Liu
Organizational Affiliation
Changhai Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Liqun Jiao
Organizational Affiliation
Xuanwu Hospital, Beijing
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of USTC
City
Hefei
State/Province
Anhui
Country
China
Facility Name
The First Affiliated Hospital of Wannan Medical College
City
Wuhu
State/Province
Anhui
Country
China
Facility Name
Cangzhou Central hospital
City
Cangzhou
State/Province
Hebei
Country
China
Facility Name
Wuhan Hospital of Traditional Chinese and Western Medicine
City
Wuhan
State/Province
Hubei
Country
China
Facility Name
General Hospital of Northen Theater Command
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
Linyi People's Hospital
City
Linyi
State/Province
Shandong
Country
China
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Facility Name
Beijing Chao-Yang Hospital, Capital Medical University
City
Beijing
Country
China
Facility Name
Xuanwu Hospital Capital Medical University
City
Beijing
Country
China
Facility Name
Changhai Hospital of Shanghai
City
Shanghai
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Single-Arm Trial of Neurovascular Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerotic Stenosis

We'll reach out to this number within 24 hrs